Valuation: IceCure Medical Ltd

Market Cap 10.55M 0 9.13M 8.52M 7.82M 14.71M 1B 14.94M 100M 39.26M 503M 39.63M 38.76M 1.66B P/E 2026 *
-0.54x
P/E 2027 * -0.8x
Enterprise Value 10.55M 0 9.13M 8.52M 7.82M 14.71M 1B 14.94M 100M 39.26M 503M 39.63M 38.76M 1.66B EV / Sales 2026 *
1.66x
EV / Sales 2027 * 0.84x
Free-Float
67.28%
Yield 2026 *
-
Yield 2027 * -
08-06 IceCure Medical Ltd. Adds Adventist Health Glendale As U.S. Clinical Site For Its Post-Marketing ChoICE Study For Low-Risk Breast Cancer Cryoablation Treatment CI
07-27 IceCure Medical Kicks Off Post-Marketing ChoICE Study for ProSense Cryoablation in Low-Risk Breast Cancer Treatment at First U.S. Clinical Site CI
07-14 IceCure Medical Expands ProSense Cryoablation System Install Base and Clinical Adoption In The United States CI
07-06 IceCure Medical Highlights Expanding Commercial Adoption Of ProSense Cryoablation In Brazil Following FDA Clearance For Breast Cancer CI
06-26 IceCure Medical Files to Register Sale of 5.5 Million Shares by Armistice MT
06-23 IceCure Medical Ltd. Highlights Peer-Reviewed Journal Article Demonstrating ProSense Cryoablation Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer CI
06-18 IceCure Medical Ltd announced that it has received $5.499819 million in funding CI
06-17 IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures MT
06-17 IceCure Medical Ltd announced that it expects to receive $5.499819 million in funding CI
05-19 IceCure Medical Ltd. Reports Nearly 90% Recurrence-Free Rate For Cryoablation Of Kidney Cancer And Showcases ProSense At ECIO 2026 CI
05-14 Icecure granted 180-day extension by Nasdaq to regain compliance with minimum bid requirement RE
05-13 IceCure Medical Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-12 IceCure Medical Ltd, Q1 2026 Earnings Call, May 12, 2026
Manager TitleAgeSince
Chief Executive Officer 65 01/09/2016
Director of Finance/CFO 50 17/05/2026
Chief Operating Officer 49 05/11/2025
Director TitleAgeSince
Director/Board Member 65 05/12/2017
Chairman 62 05/12/2017
Director/Board Member 57 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-6.22% - - 10.55M
+2.41%+3.43%+28.93%+6.88% 220B
+2.39%+5.02%+2.09%-20.96% 144B
+1.36%+7.21%-19.42%+25.07% 134B
+0.02%+5.52%-52.19%-2.51% 71.46B
+0.45%+4.24%+14.51%+14.16% 51.71B
+1.05%+7.19%-14.90%-17.93% 50.84B
+3.28%+5.49%+27.35%+13.73% 41.23B
+1.79%+7.83%+44.69%+37.11% 39.95B
+2.08%+5.51%-0.32%-2.92% 32.42B
Average +1.48%+5.55%+3.42%+5.85% 87.22B
Weighted average by Cap. +1.79%+5.17%+4.10%+4.39%

Financials

2026 *2027 *
Net sales 6.37M 0 5.51M 5.15M 4.72M 8.88M 606M 9.02M 60.37M 23.69M 304M 23.92M 23.4M 1B 12.55M 0 10.85M 10.13M 9.3M 17.49M 1.19B 17.76M 119M 46.67M 598M 47.11M 46.08M 1.98B
Net income -16.63M -0 -14.38M -13.43M -12.32M -23.17M -1.58B -23.54M -158M -61.85M -793M -62.44M -61.07M -2.62B -14.06M -0 -12.16M -11.35M -10.42M -19.59M -1.34B -19.9M -133M -52.29M -671M -52.78M -51.63M -2.22B
Net Debt - -
Logo IceCure Medical Ltd
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Employees
68
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-